Citadel Advisors LLC Purchases 163,799 Shares of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA)

Share on StockTwits

Citadel Advisors LLC raised its position in Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) by 8.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,185,409 shares of the biopharmaceutical company’s stock after purchasing an additional 163,799 shares during the quarter. Citadel Advisors LLC owned 3.20% of Dicerna Pharmaceuticals worth $34,420,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. Cubist Systematic Strategies LLC increased its stake in shares of Dicerna Pharmaceuticals by 7.1% in the second quarter. Cubist Systematic Strategies LLC now owns 28,161 shares of the biopharmaceutical company’s stock valued at $444,000 after buying an additional 1,871 shares during the period. Morgan Stanley increased its stake in shares of Dicerna Pharmaceuticals by 25.5% in the second quarter. Morgan Stanley now owns 25,331 shares of the biopharmaceutical company’s stock valued at $399,000 after buying an additional 5,149 shares during the period. AQR Capital Management LLC increased its stake in shares of Dicerna Pharmaceuticals by 11.0% in the second quarter. AQR Capital Management LLC now owns 39,643 shares of the biopharmaceutical company’s stock valued at $624,000 after buying an additional 3,919 shares during the period. Vanguard Group Inc. increased its stake in shares of Dicerna Pharmaceuticals by 1.6% in the second quarter. Vanguard Group Inc. now owns 2,339,194 shares of the biopharmaceutical company’s stock valued at $36,842,000 after buying an additional 35,905 shares during the period. Finally, Virtus ETF Advisers LLC acquired a new stake in shares of Dicerna Pharmaceuticals in the second quarter valued at about $285,000. Hedge funds and other institutional investors own 82.04% of the company’s stock.

Several equities research analysts have recently weighed in on DRNA shares. Zacks Investment Research raised Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, July 22nd. BidaskClub raised Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, August 13th. HC Wainwright set a $22.00 price target on Dicerna Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, August 26th. Cowen reaffirmed a “buy” rating on shares of Dicerna Pharmaceuticals in a research note on Tuesday, July 2nd. Finally, Citigroup raised their target price on Dicerna Pharmaceuticals from $25.00 to $30.00 and gave the stock a “buy” rating in a research note on Wednesday, July 3rd. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $21.57.

In other news, insider James B. Weissman sold 14,680 shares of the firm’s stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $13.07, for a total value of $191,867.60. Following the transaction, the insider now owns 9,800 shares in the company, valued at $128,086. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 21.28% of the stock is owned by company insiders.

Shares of DRNA stock traded up $0.09 during trading hours on Friday, reaching $14.52. The company had a trading volume of 351,201 shares, compared to its average volume of 379,535. Dicerna Pharmaceuticals Inc has a 12 month low of $9.31 and a 12 month high of $17.07. The company has a quick ratio of 3.65, a current ratio of 3.65 and a debt-to-equity ratio of 0.01. The business has a fifty day simple moving average of $13.91 and a 200-day simple moving average of $13.75.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.32) by ($0.03). Dicerna Pharmaceuticals had a negative net margin of 737.93% and a negative return on equity of 50.30%. The company had revenue of $5.68 million during the quarter, compared to the consensus estimate of $10.95 million. Sell-side analysts expect that Dicerna Pharmaceuticals Inc will post -1.31 EPS for the current fiscal year.

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases.

See Also: What does the Dow Jones Industrial Average (DJIA) measure?

Want to see what other hedge funds are holding DRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dicerna Pharmaceuticals Inc (NASDAQ:DRNA).

Institutional Ownership by Quarter for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

SOTHERLY HOTELS/SH SH  Upgraded by Zacks Investment Research to Hold
SOTHERLY HOTELS/SH SH Upgraded by Zacks Investment Research to Hold
Solaredge Technologies  Lowered to Hold at Zacks Investment Research
Solaredge Technologies Lowered to Hold at Zacks Investment Research
Resonant  Upgraded to “Hold” at Zacks Investment Research
Resonant Upgraded to “Hold” at Zacks Investment Research
Portola Pharmaceuticals  PT Lowered to $44.00
Portola Pharmaceuticals PT Lowered to $44.00
UltraNote Coin Reaches Market Cap of $13,486.00
UltraNote Coin Reaches Market Cap of $13,486.00
FS KKR Capital Corp  Receives $7.63 Consensus PT from Analysts
FS KKR Capital Corp Receives $7.63 Consensus PT from Analysts


© 2006-2019 Ticker Report